Malignant Pleural Effusion Market is Expected to Reach USD 3,736 million by 2034

The Malignant Pleural Effusion Market size across the 7MM is forecasted to rise from USD 2,423 million in 2025 to USD 3,736 million by 2034, registering a compound annual growth rate (CAGR) of 4.90% over the period. This growth trend spans major markets, including the US, EU4, the UK, and Japan.

Key Factors Driving Growth in the Malignant Pleural Effusion Market

Expanding Patient Pool in Malignant Pleural Effusion

According to DelveInsight’s analysis, the total incidence of pleural effusion across the 7MM reached approximately 4.1 million cases in 2023, with Malignant Pleural Effusion (MPE) representing around 650,000 cases. The eligible MPE patient pool was estimated at nearly 500,000 cases, predominantly from the EU4 and the United Kingdom, followed by the United States. This expanding patient population - driven by improvements in cancer survival rates, diagnostic techniques, and disease detection - is expected to fuel steady market growth and increase demand for effective treatment solutions and medical devices.

👉 Explore the Full Report: Gain a comprehensive understanding of the Malignant Pleural Effusion Market Forecast

Evolving Treatment Standards and Guideline Updates

The management of MPE primarily focuses on symptom control through procedures such as thoracentesis, talc pleurodesis (via poudrage or powder application), and indwelling pleural catheters (IPCs). Recent clinical guidelines, including updates from the British Thoracic Society and other expert groups, increasingly recommend IPCs as a first-line therapy for suitable patients. This shift is altering procedural preferences and driving greater adoption of IPCs, influencing both treatment strategies and market trends.

Competitive Landscape and Emerging Therapies

Although relatively limited, the MPE therapeutic pipeline is showing signs of expansion with several promising candidates. RS Oncology’s RSO-021 demonstrated encouraging Phase I results at ASCO 2024, showing good tolerability, minimal systemic exposure, and early efficacy signals in MPE patients. In addition, developments from Genelux Corporation and Candel Therapeutics are contributing to a growing wave of innovation in the field. New entrants - comprising biotechnology firms, device manufacturers, and academic collaborations - are actively exploring intrapleural biologics, fibrinolytics, locoregional therapies, and radiotherapeutics, signaling a potential transformation in the MPE treatment landscape.

Market Opportunities and Outlook

Given its high prevalence and palliative focus, the MPE market remains commercially significant, supported by consistent demand for procedures and devices such as IPCs and pleurodesis agents. However, progress in pharmaceutical innovation has been limited by the diverse etiology of the condition and its symptom-management-oriented treatment paradigm. Future market evolution will largely depend on the emergence of novel intrapleural therapies that can meaningfully reduce hospital readmissions and improve patients’ quality of life.

DelveInsight’s “Malignant Pleural Effusion Market Insight, Epidemiology, and Market Forecast – 2034” provides an in-depth analysis of MPE’s epidemiology, therapeutic landscape, and market trends across the United States, EU4 (Germany, France, Italy, and Spain) plus the United Kingdom, and Japan. The report includes historical and forecasted market data, treatment patterns, emerging drug assessments, and adoption trends, while also highlighting unmet medical needs and the market potential for upcoming innovations from 2020 to 2034.

👉Assess Market Opportunities: Identify potential investment and partnering opportunities in the fast-evolving Malignant Pleural Effusion therapeutic space.

Malignant Pleural Effusion Disease Understanding

Malignant Pleural Effusion Overview and Diagnosis

Malignant pleural effusion (MPE) is characterized by the accumulation of fluid and malignant cells within the pleural space - the area between the lung and the chest wall - resulting in symptoms such as shortness of breath and chest discomfort. This condition commonly occurs as a complication of various cancers. The clinical presentation of MPE can differ significantly among patients; while some remain asymptomatic, others experience severe and debilitating symptoms.

Malignant Pleural Effusion Treatment

Management of malignant pleural effusion generally focuses on symptom control and may include repeated thoracentesis, pleurodesis, or the use of indwelling pleural catheters (IPC). The choice of therapy depends on the patient’s overall health, functional status, and whether tissue sampling is needed for diagnostic purposes. In certain cases, chemotherapy, radiation therapy, or intrapleural medication infusions are employed to manage the underlying malignancy. For recurrent effusions, sclerosing agents may be administered to induce pleural fibrosis and prevent fluid reaccumulation.

Malignant Pleural Effusion Epidemiology

The epidemiology section of the Malignant Pleural Effusion report offers both historical and forecasted data, segmented by total incident cases of Pleural Effusion, total incident and diagnosed cases of Malignant Pleural Effusion, as well as cases categorized by tumor type and total treated cases. The analysis covers the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning the years 2020 to 2034.

Malignant Pleural Effusion Epidemiology Segmentation

• Total Incident Cases of Pleural Effusion
• Total Incident Cases of Malignant Pleural Effusion
• Total Diagnosed Cases of Malignant Pleural Effusion
• Total Incident Cases of Malignant Pleural Effusion by Tumor Type
• Total Treated Cases of Malignant Pleural Effusion

Malignant Pleural Effusion Companies

• RS Oncology
• Genelux Corporation
• Candel Therapeutics, and others.

Malignant Pleural Effusion Market Drivers

• Rising incidence of malignant pleural effusion (MPE) expanding the overall patient pool.
• Improved cancer survival rates and diagnostic advancements boosting case detection.
• Updated clinical guidelines promoting early adoption of indwelling pleural catheters (IPCs).
• Increasing preference for minimally invasive and outpatient treatment approaches.
• Emerging therapies like RS Oncology’s RSO-021 showing promising clinical outcomes.
• Growing R&D interest from biotech firms exploring intrapleural biologics and locoregional therapies.

👉 Book a Consultation: Speak with DelveInsight’s healthcare experts to understand evolving Malignant Pleural Effusion market dynamics and growth opportunities

Malignant Pleural Effusion Market Barriers

• Limited pharmaceutical innovation due to MPE’s complex and palliative nature.
• Heavy reliance on procedural treatments offering only symptomatic relief.
• High recurrence rates and procedural complications limiting long-term efficacy.
• Significant cost burden from repeated interventions and hospitalizations.
• Uneven reimbursement coverage and treatment access across healthcare systems.
• Lack of targeted disease-modifying therapies in the current treatment paradigm.

Scope of the Malignant Pleural Effusion Market Report

• Study Period: 2020–2034
• Coverage: 7MM [United States, Japan, EU4 & UK]
• Key Essential Thrombocythemia Companies: RS Oncology, Genelux Corporation, Candel Therapeutics, and others.

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.